Compounded Tirzepatide: Clinics & Pricing Guide

Compounded tirzepatide is prepared by compounding pharmacies using the tirzepatide active ingredient. The FDA reference file says clearly that compounded versions are not FDA-approved and should not be described as generics.

The reference notes that tirzepatide was removed from the shortage list in December 2024 and later re-added, which captures how unstable the legal backdrop can be. Patients should verify current shortage and compounding status before they treat it like a settled option.

Quality varies by compounding pharmacy, so sourcing matters. The reference recommends confirming the pharmacy is licensed and accredited, with PCAB accreditation as a useful credibility signal when patients compare programs.

From a clinic perspective, compounded tirzepatide conversations still revolve around tirzepatide-style titration, side effects, and follow-up. The real question is whether a clinic is transparent about sourcing, monitoring, and the limits of what is and is not FDA-approved.

The FDA reference lists compounded tirzepatide at roughly $300 to $600 per month, which is generally below brand-name pricing.

Prices vary by pharmacy and location, and a lower monthly quote should be weighed against sourcing quality, clinical oversight, and the shifting legal environment.

Prices vary by pharmacy, location, and clinic structure.

The big comparison is brand-name tirzepatide versus compounded tirzepatide, not just tirzepatide versus semaglutide. Brand-name options carry FDA approval for labeled uses; compounded versions do not.

That makes pharmacy quality, shortage status, and follow-up structure the main deciding issues in many clinic conversations, especially when patients are attracted by the lower quoted monthly cost.